title: Neuroendocrine tumors in the Iran Cancer Institute: predictive factors of patient survival.
abstract: BACKGROUND
  Neuroendocrine tumors have widespread and different clinical presentations and prognoses. This study was conducted to assess their survival time and prognostic factors in Iran.
  
  
  METHODS
  In a retrospective cohort study, 189 patients diagnosed of having neuroendocrine carcinoma were chosen. The tumor and clinical characteristics of the patients were modeled with a Cox proportional hazard approach. Survival was assessed using Kaplan-Meyer curves.
  
  
  RESULTS
  Crude median survival time was 30 months. Women survived longer than men (the median survival time for women was 40 and for men was 24 months). Age (<60 vs >60 years old with hazard ratio (HR) of 2.43, 95% CI 1.3-4.5), primary pathology report (carcinoid vs. others with HR 5.85 cm, 95% CI 2.4-14.3), tumor size (for 5-10, HR of 3.1, 95% CI 1.6 and for >10 HR of 8.2, 95% with 95% CI 3.1-21.9), and chemotherapy with single drug (taking vs. not taking with a HR 2.2, 95% CI 1.1-4.8) had significant effects on overall survival of patients.
  
  
  CONCLUSIONS
  Survival time in patients with neuroendocrine carcinomas is related to demographics, clinical characteristics, tumor histology, and subtype specific treatment.
authors.affiliation: Department of Internal Medicine, Cancer Research Center, Tehran University of Medical Sciences, Tehran, Iran E-mail : ssadighi@tums.ac.ir.
authors.forename: Sanambar
authors.initials: S
authors.lastname: Sadighi
authors.forename: Ghodratollah
authors.initials: G
authors.lastname: Roshanaee
authors.forename: Saba
authors.initials: S
authors.lastname: Vahedi
authors.forename: Easa
authors.initials: E
authors.lastname: Jahanzad
authors.forename: Mohammad Ali
authors.initials: MA
authors.lastname: Mohagheghi
authors.forename: Alireza
authors.initials: A
authors.lastname: Mousavi-Jarahi
mesh_terms: D000230:Adenocarcinoma / Q000401:mortality* / Q000556:secondary / Q000628:therapy; D003131:Combined Modality Therapy; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007492:Iran; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D060787:Neoplasm Grading; D009361:Neoplasm Invasiveness; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy / Q000473:pathology; D018358:Neuroendocrine Tumors / Q000401:mortality* / Q000473:pathology / Q000628:therapy; D011379:Prognosis; D012189:Retrospective Studies; D015996:Survival Rate